The Peptide NewsroomPeptide research, industry and supply-chain headlines

GLP-1 Tracked Brain Injury Recovery, but Only in Patients With Obesity

Topic card: recovery

An exploratory study published in the Journal of the Neurological Sciences reports that GLP-1 levels measured within 24 hours of a traumatic brain injury were associated with inflammation and two-week symptom scores, but only in participants with obesity. The authors describe the findings as preliminary.

GLP-1, or glucagon-like peptide-1, is the gut hormone that the weight-loss drug class imitates. Here it was not given as a drug: researchers measured what patients produced on their own after a head injury, then looked at whether those levels lined up with how people were doing two weeks later.

How the levels split

Of the 55 participants, 38.2 percent (n = 21) had an obese BMI. After controlling for age, biological sex, race and prior TBI history, that group had GLP-1 levels 21.4 percent higher within 24 hours of injury (log-estimate 0.19, 95% CI 0.003 to 0.386, p = 0.051) and 31.2 percent higher at two weeks (log-estimate 0.27, 95% CI -0.01 to 0.55, p = 0.063).

Neither of those differences cleared conventional significance, which the write-up does not hide. They are the backdrop to the more striking part of the analysis rather than the headline result.

The inflammation link

In the obesity group, GLP-1 at 24 hours was associated with interleukin-6 at two weeks (r = 0.85, p = 0.014), on just 12 participants. IL-6 is a standard inflammatory marker, and an association that tight on a sample that small is interesting and fragile in equal measure.

Symptom scores moved with it

Also in the obesity group, the change in GLP-1 from 24 hours to two weeks was inversely associated with post-concussion symptoms on the RPQ (rho = -0.84, p = 0.017), anxiety on the GAD-7 (rho = -0.74, p = 0.034) and depression on the PHQ-9 (rho = -0.86, p = 0.007). Quality of life on the QOLIBRI did not reach significance (rho = 0.70, p = 0.054), and in the 22 participants without obesity nothing was significant at all (p values 0.207 to 0.993).

Limitations

The authors call this exploratory, and the numbers justify the label: the inflammation correlation rests on 12 people, several of the group differences sit just above the significance threshold, and these are correlations, not evidence that GLP-1 is doing anything to recovery. Two weeks is also a short window for traumatic brain injury outcomes.

A biomarker, not a treatment

What the authors conclude is narrow: a link between GLP-1, IL-6 and clinical response to TBI in patients with obesity. Whether that makes GLP-1 a useful recovery biomarker, and whether the obesity split holds in a larger cohort, is exactly what this study cannot answer.

Source: Journal of the neurological sciences. Read the original.

Filed under: recovery

Comments (0)

Discussion happens on Reddit.
Questions and corrections go to r/PeptideNewsroom.

Go to r/PeptideNewsroom

Corrections are the most useful thing you can post. Comments touching dosing, sourcing or links are held for a moderator first.

More from The Peptide Newsroom

Engineered ICOSL Peptide Cuts Proteinuria in Mice, But No Human Trials Yet

Researchers engineered a 19-amino-acid peptide from inducible co-stimulator ligand that blocks alpha-v-beta-3 integrin on kidney podocytes, reducing urinary protein across several rodent models. The work is entirely preclinical, tested a single dose, and human trials have not begun.

Nerve Peptide CGRP Draws Interest in Diabetic Wound Repair, But Infection Risk Looms

A Frontiers in Endocrinology mini review synthesizes preclinical evidence that the nerve peptide CGRP coordinates dead-cell clearance in diabetic wounds, mostly in mouse models. The same signaling suppressed antibacterial defenses in infection studies, a tension the authors flag before anyone reaches for a therapy.

Peptide Combination Trial Reports Walking Gains After Complete Spinal Cord Injury, But Data Remain Preliminary

A preprint randomized trial of 30 people with complete spinal cord injury reports that NVG-291 plus thymosin beta-4 added to rehabilitation was associated with larger motor and walking gains than placebo over 12 months. No AIS grade conversions occurred, and the study is a single-center preprint awaiting peer review.